<DOC>
	<DOCNO>NCT01783444</DOCNO>
	<brief_summary>This study ass efficacy tolerability everolimus capecitabine monotherapies compare everolimus/exemestane combination woman ER + advance breast cancer .</brief_summary>
	<brief_title>A Phase II Study Everolimus Combination With Exemestane Versus Everolimus Alone Versus Capecitabine Advance Breast Cancer .</brief_title>
	<detailed_description>This three-arm , randomize , open label , multi-center phase II study investigate combination everolimus ( 10mg daily ) exemestane ( 25mg daily ) versus everolimus ( 10mg daily ) versus capecitabine ( 1250mg/m2 twice daily 14 day , 3-week cycle ) patient estrogen-receptor positive , HER2 negative , advanced breast cancer recurrence progression letrozole anastrozole . The reference therapy ( control arm ) use course trial combination arm everolimus plus exemestane . The investigational therapy context study everolimus monotherapy capecitabine monotherapy . All treatment take orally disease progression , intolerable toxicity withdrawal patient 's informed consent . Patients randomly assign equal allocation one treatment arm : 1 . Exemestane ( 25mg daily ) combination everolimus ( 10mg daily ) 2 . Everolimus ( 10mg daily ) 3 . Capecitabine ( 1250mg/m2 twice daily ) orally two week , follow one week rest period 3-weeks cycle . Treatment assignment stratify presence visceral disease ( yes vs. ) . Visceral refers lung , liver , heart , ovary , spleen , kidney , adrenal gland , malignant pleural pericardial effusion malignant ascites .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Women locally advance , recurrent , metastatic breast cancer along confirmation estrogenreceptor positive ( ER+ ) . Measurable disease define least one lesion ≥ 10 mm CT MRI accurately measure least one dimension ( CT scan slice thickness ≤ 5 mm ) OR • Bone lesion : lytic mixed ( lytic + blastic ) absence measurable disease define Patients receive one chemotherapy line . Patients nonmeasurable lesion lytic mixed ( lytic blastic ) bone metastasis.Previous treatment exemestane , mTOR inhibitor , PI3K inhibitor AKT inhibitor Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Estrogen receptor positive , locally advanced , metastatic breast cancer</keyword>
</DOC>